ProFunds Pharmaceuticals UltraSector ProFund Svs (PHPSX)
18.24
-0.02
(-0.11%)
USD |
May 30 2025
Key Stats
Customize
| Net Expense Ratio | Total Assets Under Management | Weighted Average Dividend Yield | Turnover Ratio (Generic) |
|---|---|---|---|
| 2.78% | 2.246M | 1.42% | 207.0% |
| 1 Year Fund Level Flows | 1 Year Total Returns (Daily) | Annualized Total Returns Since Inception (Daily) | Max Drawdown (Since Inception) |
| -682779.0 | -3.64% | Upgrade | Upgrade |
Basic Info
| Investment Strategy | |
| The Fund seeks daily investment results, before fees and expenses, that correspond to one and one-half times the return of the Dow Jones U.S. Select Pharmaceuticals Index for a single day. The Index seeks to measure the performance of certain companies in the pharmaceuticals sector of the U.S. equity market. |
| General | |
| Security Type | Mutual Fund |
| Broad Asset Class | Miscellaneous |
| Broad Category | Equity |
| Global Peer Group | Alternative Equity Leveraged |
| Peer Group | Equity Leverage Funds |
| Global Macro | Alternative Equity |
| US Macro | Large-Cap Funds |
| YCharts Categorization | -- |
| YCharts Benchmark | -- |
| Prospectus Objective | Equity Leverage Funds |
| Fund Owner Firm Name | ProFunds |
| Broad Asset Class Benchmark Index | |
| ^SPXTR | 100.0% |
Net Fund Flows Versus Peer Group
1 Month
% Rank:
74
-1.543B
Peer Group Low
1.158B
Peer Group High
1 Year
% Rank:
55
-682779.0
-1.688B
Peer Group Low
5.503B
Peer Group High
3 Months
% Rank:
58
-931.83M
Peer Group Low
3.410B
Peer Group High
3 Years
% Rank:
48
-5.108B
Peer Group Low
4.441B
Peer Group High
6 Months
% Rank:
59
-1.316B
Peer Group Low
3.256B
Peer Group High
5 Years
% Rank:
53
-2.725B
Peer Group Low
5.207B
Peer Group High
YTD
% Rank:
57
-1.193B
Peer Group Low
2.811B
Peer Group High
10 Years
% Rank:
63
-3.454B
Peer Group Low
6.344B
Peer Group High
Date Unavailable
Risk
Performance Versus Peer Group
Annual Total Returns Versus Peers
As of June 01, 2025.
Asset Allocation
As of January 31, 2025.
| Type | % Net |
|---|---|
| Cash | 19.48% |
| Stock | 80.39% |
| Bond | 0.00% |
| Convertible | 0.00% |
| Preferred | 0.00% |
| Other | 0.13% |
Top 10 Holdings
| Name | % Weight | Price | % Change |
|---|---|---|---|
|
Societe Generale (London Branch) Repo
|
5.05% | -- | -- |
|
HSBC Securities (USA) Inc REPO
|
4.62% | -- | -- |
|
Intra-Cellular Therapies Inc ORD
|
4.41% | -- | -- |
|
USD Cash
|
3.86% | -- | -- |
| Royalty Pharma PLC | 3.66% | 32.88 | 0.74% |
| Corcept Therapeutics Inc | 3.25% | 77.56 | -0.10% |
| Axsome Therapeutics Inc | 3.17% | 105.16 | 0.50% |
| Pfizer Inc | 3.07% | 23.49 | 0.17% |
| Bristol-Myers Squibb Co | 3.04% | 48.28 | 0.90% |
| Johnson & Johnson | 3.02% | 155.21 | 1.06% |
Fees & Availability
| Fees | |
| Actual 12B-1 Fee | 1.00% |
| Actual Management Fee | 0.03% |
| Administration Fee | 1.54K% |
| Maximum Front Load | -- |
| Maximum Deferred Load | -- |
| Maximum Redemption Fee | -- |
| General Availability | |
| Available for Insurance Product | -- |
| Available for RRSP | -- |
| Purchase Details | |
| Open to New Investors |
|
| Minimum Initial Investment | 5000.00 None |
| Minimum Subsequent Investment | 100.00 None |
Basic Info
| Investment Strategy | |
| The Fund seeks daily investment results, before fees and expenses, that correspond to one and one-half times the return of the Dow Jones U.S. Select Pharmaceuticals Index for a single day. The Index seeks to measure the performance of certain companies in the pharmaceuticals sector of the U.S. equity market. |
| General | |
| Security Type | Mutual Fund |
| Broad Asset Class | Miscellaneous |
| Broad Category | Equity |
| Global Peer Group | Alternative Equity Leveraged |
| Peer Group | Equity Leverage Funds |
| Global Macro | Alternative Equity |
| US Macro | Large-Cap Funds |
| YCharts Categorization | -- |
| YCharts Benchmark | -- |
| Prospectus Objective | Equity Leverage Funds |
| Fund Owner Firm Name | ProFunds |
| Broad Asset Class Benchmark Index | |
| ^SPXTR | 100.0% |
Fundamentals
| General | |
| Distribution Yield | -- |
| Dividend Yield TTM (5-30-25) | 0.00% |
| 30-Day SEC Yield | -- |
| 7-Day SEC Yield | -- |
| Stock | |
| Weighted Average PE Ratio | 27.51 |
| Weighted Average Price to Sales Ratio | 8.658 |
| Weighted Average Price to Book Ratio | 7.604 |
| Weighted Median ROE | -38.88% |
| Weighted Median ROA | -9.10% |
| ROI (TTM) | -11.67% |
| Return on Investment (TTM) | -11.67% |
| Earning Yield | 0.0624 |
| LT Debt / Shareholders Equity | 3.180 |
As of January 31, 2025
Growth Metrics
| EPS Growth (1Y) | 14.01% |
| EPS Growth (3Y) | 4.52% |
| EPS Growth (5Y) | -3.71% |
| Sales Growth (1Y) | 14.61% |
| Sales Growth (3Y) | 22.71% |
| Sales Growth (5Y) | 13.30% |
| Sales per Share Growth (1Y) | 53.36% |
| Sales per Share Growth (3Y) | 19.75% |
| Operating Cash Flow - Growth Ratge (3Y) | 7.59% |
As of January 31, 2025
Fund Details
| Key Dates | |
| Inception Date | 6/28/2000 |
| Last Annual Report Date | 7/31/2024 |
| Last Prospectus Date | 11/27/2024 |
| Share Classes | |
| PHPIX | Inv |
| Attributes | |
| Index Fund | -- |
| Inverse Fund | -- |
| Leveraged Fund |
|
| Fund of Funds | No |
| Currency Hedged Fund | -- |
| Synthetic Replication Fund | No |
Top Portfolio Holders
| Name | % Weight |
|---|---|
| Portfolio A | 5.00% |
| Portfolio B | 3.50% |
| Portfolio C | 2.25% |
Excel Add-In Codes
| Name: =YCI("M:PHPSX", "name") |
| Broad Asset Class: =YCI("M:PHPSX", "broad_asset_class") |
| Broad Category: =YCI("M:PHPSX", "broad_category_group") |
| Prospectus Objective: =YCI("M:PHPSX", "prospectus_objective") |
| To find the codes for any of our securities and financial metrics, see our Complete Excel Reference. |